Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug. Market analysts and industry participants are closely tracking the development to assess its impact on consumer pricing, liquidity, and domestic business sentiment over the coming quarters.